Expert characterization is the basis of care. Prognostic heterogeneity is guiding therapeutic aggressiveness, early sequelae should be avoided. At the metastatic stage, therapy remains palliative. Standards have been established thanks to the recent phase III trial inplementations. Discovery of new therapeutic options is major goal for the future.
|Translated title of the contribution||Therapeutic management of neuroendocrine neoplasms|
|Number of pages||10|
|Journal||Correspondances en MHND|
|State||Published - Sep 2016|
- Locoregional therapy
- Neuro endocrine
- Targeted therapy